Martin Figeac

This study uses patient-derived tumor organoids to predict HNSCC patient outcomes, finding strong associations between organoid responses to cisplatin and X-rays and clinical prognosis.

This study shows that lncRNA UCA1 influences chromatin remodeling via the SWI/SNF complex in colorectal cancer, affecting stem-cell properties and drug response.

The paper shows that MET exon 14 skipping mutations eliminate the pro-apoptotic function of MET, converting it from a tumor suppressor to an oncogenic driver in lung adenocarcinomas.

The paper identifies a regulatory network involving ETS1, FOSL1, and SMAD3 that mediates MET exon 14 skipping in lung cancer, showing their role in RAS-ERK pathway activation and potential as therapeutic targets.

This study establishes patient-derived ovarian cancer organoids that mimic tumor characteristics and drug responses, showing potential for precision medicine.

This paper identifies N-lobe MET mutations in HPRCC that require ligand stimulation for activation, unlike kinase domain mutations, and shows their sensitivity to MET inhibitors.

FiLT3r is an alignment-free algorithm that accurately detects FLT3-ITDs in HTS data with high precision and low resource usage.

The paper identifies transcriptomic signatures of brain regional vulnerability to Parkinson’s disease by analyzing gene expression patterns across Braak Lewy body stages in human brain datasets.